Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Queensland Health
Medtronic
Deloitte
Boehringer Ingelheim
Farmers Insurance
Julphar
Johnson and Johnson
Accenture

Generated: December 18, 2018

DrugPatentWatch Database Preview

YONDELIS Drug Profile

« Back to Dashboard

When do Yondelis patents expire, and when can generic versions of Yondelis launch?

Yondelis is a drug marketed by Janssen Prods and is included in one NDA. There is one patent protecting this drug.

This drug has forty-two patent family members in thirty-five countries.

The generic ingredient in YONDELIS is trabectedin. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the trabectedin profile page.

Summary for YONDELIS
Drug patent expirations by year for YONDELIS
Generic Entry Opportunity Date for YONDELIS
Generic Entry Date for YONDELIS*:
Constraining patent/regulatory exclusivity:
PEDIATRIC EXCLUSIVITY
NDA:
Dosage:
POWDER;IV (INFUSION)

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for YONDELIS
Drug ClassAlkylating Drug
Mechanism of ActionAlkylating Activity
Synonyms for YONDELIS
(1'R,6R,6aR,7R,13S,14S,16R)-6',8,14-Trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-19-oxo-3',4',6,7,12,13,14,16-octahydrospiro(6,16-(epithiopropanooxymethano)-7,13-imino-6aH-1,3-dioxolo(7,8)isoquino(3,2-b)(3)benzazocine-20,1'(2'
(1R,2R,3R,11S,12S,14R,26R)-5,6',12-trihydroxy-6,7'-dimethoxy-7,21,30-trimethyl-27-oxo-3',4'-dihydro-2'H-17,19,28-trioxa-24-thia-13,30-diazaspiro[heptacyclo[12.9.6.1;{3,11}.0;{2,13}.0;{4,9}.0;{15,23}.0;{16,20}]triacontane-26,1
(6R,6aR,7R,13S,14S,16R,20R)-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-19-oxo-3',4',6,7,12,13,14,16-octahydro-2'H,6aH-spiro[7,13-epimino-6,16-(epithiopropanooxymethano)[1,3]dioxolo[7,8]isoquinolino[3,2-b][3]benzazoci
114899-77-3
87541-EP2298780A1
87541-EP2305689A1
AC-27767
AC1L33FK
AKOS025401985
AN-5365
C39H43N3O11S
CAS-114899-77-3
CCRIS 8133
CHEBI:84050
CHEMBL450449
CS-1608
D03RTK
DB05109
DSSTox_CID_26880
DSSTox_GSID_46880
DSSTox_RID_81984
DTXSID2046880
Ect 743
Ecteinascidin
ecteinascidin 743
Ecteinascidin 743;ET-743;Ecteinascidin
Ecteinascidin 743|||ET-743|||Yondelis|||NSC-684766
Ecteinascidin-743
ecteinascidine
Ecteinascidine 743
Et 743
ET-743
ET743
GTPL2774
HY-50936
ID0YZQ2TCP
LS-146121
NCGC00181159-01
NCGC00181159-02
NSC 648766
NSC 684766
NSC-684766
PKVRCIRHQMSYJX-AIFWHQITSA-N
SCHEMBL12119916
Spiro(6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo(7,8)isoquino(3,2,-b)(3)benzazocine-20,1'(2'H)-isoquinolin)-19-one, 3',4',6,6a,7,13,14,16-octahydro-5-(acetyloxy)-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimet
Spiro(6,16-(epithiopropanoxymethano)-7,13-imino-12H-1,3-dioxolo(7,8)isoquino(3,2,-b)(3)benzazocine-20,1'(2'H)-isoquinolin)-19-one, 5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimet
Tox21_112762
Tox21_113236
Trabectedin
Trabectedin [INN]
Trabectedin [USAN:INN:BAN]
UNII-ID0YZQ2TCP
X5006
Yondelis (TN)
Z-3121
ZINC150338708

US Patents and Regulatory Information for YONDELIS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Prods YONDELIS trabectedin POWDER;INTRAVENOUS 207953-001 Oct 23, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Janssen Prods YONDELIS trabectedin POWDER;INTRAVENOUS 207953-001 Oct 23, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Janssen Prods YONDELIS trabectedin POWDER;INTRAVENOUS 207953-001 Oct 23, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Janssen Prods YONDELIS trabectedin POWDER;INTRAVENOUS 207953-001 Oct 23, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Janssen Prods YONDELIS trabectedin POWDER;INTRAVENOUS 207953-001 Oct 23, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Janssen Prods YONDELIS trabectedin POWDER;INTRAVENOUS 207953-001 Oct 23, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Janssen Prods YONDELIS trabectedin POWDER;INTRAVENOUS 207953-001 Oct 23, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Queensland Health
Medtronic
Deloitte
Boehringer Ingelheim
Farmers Insurance
Julphar
Johnson and Johnson
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.